Hawaii's Memory Ctr continue to offer *Leqembi* to Patients since 2019 after contributing the only Native Hawaiian Pacific Islander Diversity data to CLARITY trial leading to 2023 FDA approval.

Since 2019, neurologists & researchers at Hawaii Memory Disorders Center & Hawaii Alzheimer's Research Unit , Ct for Neuroscience Diversity participated in the investigation of Leqembi's (Lecanemab) and contributed the only Native Hawaiian and Pacific Islander diversity data in the CLARITY trial among 1,795 patients leading to FDA full approval in 2023.

According to FDA website, Alzheimer's disease is an irreversible, progressive brain disorder affecting more than 6.5 million Americans. Leqembi demonstrated a statistically significant and clinically meaningful reduction of decline from baseline to 18 months compared to placebo.

Clarity AD Baseline Characteristics

Demographic Characteristics

Characteristic	Combined Total N=1795	United States N=948
Age, median (range), years	72 (50, 90)	73(50,90)
Age Group, n (%)		
<65 years	353 (19.7)	158 (16.7)
≥65 to <80	1203 (67.0)	637 (67.2)
≥80	239 (13.3)	153 (16.1)
Female , n (%)	938 (52.3)	487 (51.4)
Region, n (%)		
North America	1072 (59.7)	948 (100)
Europe	429 (23.9)	0
Asia-Pacific	294 (16.4)	0
Race, n (%)		
Asian	303 (16.9)	7 (<1)
Black	47 (2.6)	43 (4.5)
Caucasian	1381 (76.9)	896 (94.5)
Native American	2 (<1)	1 (<1)
Native Hawaiian or Other Pacific Islander	1 (<1)	1 (<1)
Other	33 (1.8)	0
Missing	28 (1.6)	0

The most common side effects of Leqembi were headache, infusion-related reactions and amyloid-related imaging abnormalities (ARIA), most commonly presents as temporary swelling in areas of the brain usually resolves over time and may be accompanied by small spots of bleeding. Although ARIA is often not associated with any symptoms, symptoms can occur and include headache, confusion, dizziness, vision changes and nausea.

Since 2019, patients have been closely monitored for these side effects after receiving Lequembi at Neuro IV Infusion Center specifically designed to monitor and manage side effect such as ARIA by team of experienced onsite infusion and neuroscience team which is important as Leqembi is now offered to eligible patients after FDA approval 2023.

Our Hawaii patients, caregivers, families, neurologists & researchers are honored to be able to play a role to contribute diversity and inclusion of Minority Populations to this important research study leading to the FDA full approval of Leqembi" Kore Kai Liow, MD, Neurologist & Principal Investigator, Hawaii Memory Disorders Center & Alzheimer's Research Unit Clinical Professor of Medicine (Neurology), University of Hawaii John Burns School of Medicine. NIH website listing the Hawaii Trial Site ***Hawaii Alzheimer's Research Unit Hotline (808) 564-6141 or info@HawaiiNeuroscience.com***